Cutaneous Leishmaniasis: Recognition and Treatment



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2004 Mar 15;69(6):1455-1460.

Cutaneous leishmaniasis is a parasitic disease occurring throughout the Americas from Texas to Argentina, and in the Old World, particularly the Middle East and North Africa. It is spread by the female sandfly. The condition is diagnosed every year in travelers, immigrants, and military personnel. Physicians in the United States must be alert to the diagnosis of leishmaniasis in travelers returning from endemic areas. Physicians working for short periods in endemic areas often must make the diagnosis and should be aware of local disease patterns. When faced with a possible leishmanial skin lesion, a skin scraping with microscopic analysis is the best test. Punch biopsies with tissue-impression smears also can be diagnostic. Needle aspiration of tissue fluid from the margin of a lesion can yield fluid for culture to isolate the organism and identify the species. Immunologic tests are being developed, including a highly sensitive polymerase chain reaction test. The treatment mainstay is pentavalent antimony (e.g., sodium stibogluconate). Not all patients require treatment; many lesions heal spontaneously. Antimonials have a high incidence of reversible adverse effects. Other medications used for treatment include amphotericin B, pentamidine isethionate, paromomycin, and antifungals. This disease must be considered in at-risk patients, and family physicians should know the basics of diagnosis and where to go for more help.

Leishmaniasis is endemic in 88 countries throughout Africa, Asia, Europe, and North and South America.1 There are an estimated 12 million casesworldwide, with 1.5 to 2 million new cases each year. Although the incidence of leishmaniasis is greater in the Old World than in the New World, the U.S. traveler is most likely to contract this disease in Latin America. Fifty to 100 cases of New World cutaneous leishmaniasis are diagnosed each year in the United States. They are contracted mainly in Peru and Brazil, although the disease is endemic and can be contracted in any country from Mexico to Argentina, except Uruguay and Chile.2 There also is an endemic focus in Texas. Leishmaniasis is a disease associated with rural areas and poverty, but it has adapted to the urban environment as well.

In World War II, there was a high incidence of leishmaniasis and sandfly fever in troops deployed to the Persian Gulf region. In the Gulf War (1990 to 1991), approximately 697,000 U.S. troops were deployed in this region. Only 19 cases of cutaneous leishmaniasis and 12 cases of visceral disease were diagnosed in this group. The improvement came about because of the use of insecticides and repellents, lower transmission rates in the summer, and more time spent in urban areas.3,4 About 150 cases of leishmaniasis have reportedly been diagnosed in U.S. soldiers serving in Iraq in 2003, and more are expected.5 Preliminary data on 22 cases of cutaneous leishmaniasis contracted by American troops in Afghanistan, Kuwait, and Iraq and treated at Walter Reed Army Medical Center between August 2002 and September 2003 were recently released.6 The majority of these persons were infected with Leishmania major in urban areas of Iraq after a median period of deployment of 60 days.

The Leishmania protozoan was first described in 1903 by Leishman and Donovan, working separately.2 Since then, this organism has been found to be a complex grouping of species, at least 20 of which cause infections in humans. Some species cause visceral leishmaniasis, some cause cutaneous disease, and some cause both. Visceral leishmaniasis is a systemic infection characterized by fever, weight loss, and hepatosplenomegaly, and it is usually fatal without treatment. This article focuses on cutaneous leishmaniasis, the more common form of the disease.

Life Cycle and Vector

The promastigote form of the parasite is a motile form with an anterior flagellum that develops in the sandfly, the insect vector. The promastigote form develops into a metacyclic infectious form over approximately 10 days. The parasite enters the human host with the bite of the sandfly and is pulled into macrophages by ingestion. Leishmania are able to survive the acidic environment of the lysosome and become amastigote forms. These forms are obligate, intracellular, non-motile, and about 2.5 to 7 microns in diameter. It is this amastigote form that causes disease in humans and affects cellular immunity. Eventually, a sandfly will pick up this form while feeding, and it will develop into the promastigote form again in the insect.

The sandfly vector is a 2-mm long, hairy fly of the genus Phlebotomus in the Old World and Lutzomyia in the New World. These flies are able to pass through the usual netting used for mosquitoes. Sandflies are found around human habitations and breed in specific organic wastes such as feces, manure, rodent burrows, and leaf litter.7

FIGURE 1

Cutaneous leishmaniasis in a young patient in Honduras.

View Large


FIGURE 1

Cutaneous leishmaniasis in a young patient in Honduras.


FIGURE 1

Cutaneous leishmaniasis in a young patient in Honduras.

Cutaneous Leishmaniasis

Cutaneous leishmaniasis occurs in the New World and the Old World. Old World disease primarily is caused by Leishmania tropica in urban areas and Leishmania major in dry desert areas. The two subgenera of interest in Latin America are Leishmania leishmania (e.g., Leishmania mexicana, Leishmania amazonensis, Leishmania chagasi) and Leishmania viannia (e.g., Leishmania panamensis, Leishmania braziliensis, Leishmania guyanensis). The incubation period is two to eight weeks, although longer periods have been noted. The disease begins as an erythematous papule at the site of the sandfly bite on exposed parts of the body. The papule increases in size and becomes a nodule. It eventually ulcerates and crusts over. The border is usually raised and distinct. There may be multiple lesions, especially when the patient has encountered a nest of sandflies. The ulcer is typically large but painless unless there is secondary bacterial or fungal infection.

Old World leishmaniasis and L. mexicana lesions tend to heal spontaneously in months, but L. braziliensis may take years to heal. After healing, a depressed scar remains that is usually round but can be irregular. Figure 1 shows a typical leishmaniasis lesion before treatment. Satellite lesions with a nodular lymphangitis resembling sporotrichosis have been described.

Cutaneous leishmaniasis can become disseminated (diffuse cutaneous leishmaniasis), especially in immunosuppressed persons. This illness can go on for years and does not heal spontaneously. Patients with human immunodeficiency virus (HIV) infection are particularly susceptible. Other unusual types of cutaneous disease include leishmaniasis recidivans, in which small nodules develop around a healed scar, and post–kalaazar dermal leishmaniasis, in which widespread cutaneous lesions arise after a visceral infection. These conditions occur primarily in the Old World.

The mucosal form usually occurs after an initial cutaneous infection. Ninety percent of cases of mucosal leishmaniasis are found in Brazil, Bolivia, and Peru, and they usually begin in the nose or palate.8  Lesions progress to destruction of mucosa and even cartilage. They result in scarring and disfigurement and can cause pulmonary aspiration and death. Table 1 lists the differential diagnosis for cutaneous and mucosal leishmaniasis.9

Diagnosis

When physicians assess a patient with suspected leishmaniasis in the United States, the travel and military histories are most important. Patients who served in the military in the Middle East can return with this infection. Risk factors for HIV should be solicited, including sexual encounters, intravenous drug use, and blood transfusions obtained abroad.

The basic diagnostic tests are summarized in Table 2. Cutaneous scraping is the simplest and most common test, but it is only 70 to 75 percent sensitive.2 Proper cleaning and drying of the site are essential before scraping. Scrapings are made from the center and the margin of the ulcer. L. mexicana yields more organisms than L. braziliensis, and older lesions (more than four months) have fewer parasites than newer ones.

Multiple slides should be made. They are fixed with methanol, stained with Giemsa, and examined under oil immersion. Amastigotes are seen in monocytes or extracellularly. Slides must be examined completely before they can be called negative. It is important to see the nucleus and the rod-shaped kinetoplast, a mitochondrial structure containing extranuclear DNA, to diagnose leishmaniasis. The kinetoplast differentiates Leishmania from other small organisms such as Histoplasma.

Treatment

Treatment with antimonials will heal lesions faster and prevent relapse, local dissemination, mucosal disease (usually), and transmission. Not all lesions require treatment. Old World disease tends to be self-healing, and systemic treatment seldom is used. New World lesions more often require systemic treatment. Table 3 gives reasons to consider early treatment.

TABLE 1

Differential Diagnosis of Leishmaniasis

Cutaneous leishmaniasis Mucosal leishmaniasis

Bacterial skin infections

Behçet’s syndrome

Blastomycosis

Discoid lupus erythematosus

Cutaneous anthrax

Histoplasmosis

Eczema

Lethal midline granuloma

Fungal skin infections

Neoplasms

Leprosy

Paracoccidioidomycosis

Mycobacterium marinum

Rhinoscleroma

Myiasis

Sarcoidosis

Sarcoidosis

Syphilis

Skin cancer

Tuberculosis

Sporotrichosis

Wegener’s granulomatosis

Syphilis

Yaws

Tuberculosis

Yaws

Verrucous lesions


Information from reference 9.

TABLE 1   Differential Diagnosis of Leishmaniasis

View Table

TABLE 1

Differential Diagnosis of Leishmaniasis

Cutaneous leishmaniasis Mucosal leishmaniasis

Bacterial skin infections

Behçet’s syndrome

Blastomycosis

Discoid lupus erythematosus

Cutaneous anthrax

Histoplasmosis

Eczema

Lethal midline granuloma

Fungal skin infections

Neoplasms

Leprosy

Paracoccidioidomycosis

Mycobacterium marinum

Rhinoscleroma

Myiasis

Sarcoidosis

Sarcoidosis

Syphilis

Skin cancer

Tuberculosis

Sporotrichosis

Wegener’s granulomatosis

Syphilis

Yaws

Tuberculosis

Yaws

Verrucous lesions


Information from reference 9.

TABLE 2

Diagnostic Tests for Cutaneous Leishmaniasis

Test Procedure

Cutaneous scraping

Administer local anesthesia. Clean ulcer of crust, and dry with gauze. Scrape margin and central area of ulcer, and prepare five slides.

Punch biopsy

Punch 2 to 3 mm along active border; make tissue-impression smears from a biopsy sample by rolling the cut portion on a slide after blotting excess blood.

Needle aspirate

This test is useful with nodular and papular lesions, using 0.1 mL of preservative-free saline injected into the border through intact skin. Fluid is aspirated while the needle is moved back and forth under the skin; the fluid is useful for culture (blood agar Nicolle-Novy-MacNeal media).

Immunologic tests

Antibodies are detected most consistently in mucosal disease. Polymerase chain reaction test is highly sensitive but not standardized. Test is species specific.

Skin test

Test is no longer available in the United States.

TABLE 2   Diagnostic Tests for Cutaneous Leishmaniasis

View Table

TABLE 2

Diagnostic Tests for Cutaneous Leishmaniasis

Test Procedure

Cutaneous scraping

Administer local anesthesia. Clean ulcer of crust, and dry with gauze. Scrape margin and central area of ulcer, and prepare five slides.

Punch biopsy

Punch 2 to 3 mm along active border; make tissue-impression smears from a biopsy sample by rolling the cut portion on a slide after blotting excess blood.

Needle aspirate

This test is useful with nodular and papular lesions, using 0.1 mL of preservative-free saline injected into the border through intact skin. Fluid is aspirated while the needle is moved back and forth under the skin; the fluid is useful for culture (blood agar Nicolle-Novy-MacNeal media).

Immunologic tests

Antibodies are detected most consistently in mucosal disease. Polymerase chain reaction test is highly sensitive but not standardized. Test is species specific.

Skin test

Test is no longer available in the United States.

Pentavalent antimony remains the treatment of choice. It is thought to work by inhibition of adenosine triphosphate synthesis. The antimonial agent used in the United States is sodium stibogluconate (Pentostam). This drug is available from the Centers for Disease Control and Prevention (CDC), which also can assist with the investigational new drug paperwork.

Pentavalent antimonials have a high incidence of side effects, but the latter are reversible. In a military study,10 96 subjects with leishmaniasis (83 cases were cutaneous) were treated for 20 to 28 days and followed for one year. Side effects included aching, arthralgia, fatigue, gastrointestinal upset, elevation of amylase, lipase, and liver enzyme levels, leukopenia, anemia, and electrocardiographic abnormalities.

In general, more adverse reactions are expected in patients with liver and renal impairment, cardiac arrhythmias, and prolonged QT intervals; in small children; in pregnant and breastfeeding women; and in obese, elderly, and immunocompromised patients. There are no known drug interactions, but hepatotoxic drugs, including alcohol, and drugs that prolong the QT interval should be avoided.10 Because pentavalent antimony is difficult to use, consultation with an infectious disease specialist and the CDC is recommended before using it.

After 20 days of treatment with pentavalent antimonials, there is usually evidence of healing, but lesions may not be re-epithelialized completely. They generally go on to heal. Healing is determined by a healed appearance at two months, no relapse at 12 months, and no subsequent mucosal disease. Mucosal disease requires a longer treatment course and is more difficult to cure.

TABLE 3

Reasons to Treat Cutaneous Leishmaniasis

Cosmetically unacceptable lesions

Chronic lesions

Large lesions

Lesions in immunosuppressed patients

Lesions over joints

Mucosal disease

Multiple lesions

Nodular lymphangitis

Worsening lesions

TABLE 3   Reasons to Treat Cutaneous Leishmaniasis

View Table

TABLE 3

Reasons to Treat Cutaneous Leishmaniasis

Cosmetically unacceptable lesions

Chronic lesions

Large lesions

Lesions in immunosuppressed patients

Lesions over joints

Mucosal disease

Multiple lesions

Nodular lymphangitis

Worsening lesions

Trauma can reactivate the disease, so elective surgery is contraindicated for one year, and pregnancy is inadvisable for one to two months after treatment. The aching, which can be debilitating, usually resolves one week after treatment is finished but can take up to two months to go away.

Table 4 includes the recommended dosage of pentavalent antimony and other treatment options.1119 A recent randomized, double-blind, placebo-controlled study of more than 200 patients with cutaneous L. major demonstrated that oral fluconazole (Diflucan) in a dosage of 200 mg daily for six weeks was a well-tolerated and effective treatment option.18 [SOR B, single randomized controlled trial (RCT)].

The CDC is ready to assist with the diagnosis and treatment of leishmaniasis and can be contacted at 404–488–4050 or 404–639–3670.

Prevention

Vaccine development is under way. The combination of killed promastigotes plus bacille Calmette-Guérin vaccine is being tested in Iran, Sudan, and Ecuador.20 Avoiding sandflies is important but difficult, because they have adapted to urban environments. The use of insecticides in endemic areas is important for travelers. House and space spraying have reduced sandfly populations, and fine-weave pyrethroid-impregnated bed-nets have been used in Burkina Faso, Sudan, and Columbia. Destruction of rodent reservoirs by pumping insecticides into rodent burrows has had limited success.7

A recent randomized study in Venezuela evaluated the effectiveness of pyrethroid-impregnated curtains in an urban area with an incidence of cutaneous leishmaniasis of 4 percent. In 569 homes, 2,913 inhabitants were included in this study. Use of the curtains reduced the sandfly population and, 12 months after the installation of these curtains, the incidence of cutaneous leishmaniasis dropped to zero.21 [SOR B, single RCT]

TABLE 4

Treatment of Cutaneous Leishmaniasis

Pentavalent antimony

Meglumine antimoniate (Glucantime) and sodium stibogluconate (Pentostam); cure rate 94 percent; eliminated by kidneys

Dosage: 20 mg per kg per day for 20 days

Stibogluconate supplied as 100 mg Sb per mL light-sensitive solution

Calculated dose (12 to 20 mL for adults) is diluted in 50 mL of 5 percent dextrose in distilled water, infused intravenously over 10 to 15 minutes

Amphotericin B (Fungizone)

Reserved for antimony failures

Dosage: 0.5 to 1.0 mg per kg every other day for up to eight weeks; total dosage is 1.5 to 2 g for the treatment period

Pentamidine isethionate (Pentam 300)

Dosage: 2 mg per kg intramuscularly every other day for seven days

Toxic effects: damage to pancreas, kidney, or bone marrow may be irreversible

May induce diabetes mellitus

Others

Topical paromomycin is effective with L. major and L. mexicana. It can be combined with antimonials to reduce the number of injections.

Oral antifungals have demonstrated conflicting results, although some good results have been achieved with L. mexicana19 and L. major.18

Allopurinol (Zyloprim) incorporates into parasite RNA with lethal effect. Studies are conflicting, and it is not recommended, although there is synergistic activity with antimonials.1114

Heat1516 and cryotherapy17 show good results in uncontrolled trials.

Excision is not recommended because of the high risk of local relapse and disfiguration.


Information from references 11 through 19.

TABLE 4   Treatment of Cutaneous Leishmaniasis

View Table

TABLE 4

Treatment of Cutaneous Leishmaniasis

Pentavalent antimony

Meglumine antimoniate (Glucantime) and sodium stibogluconate (Pentostam); cure rate 94 percent; eliminated by kidneys

Dosage: 20 mg per kg per day for 20 days

Stibogluconate supplied as 100 mg Sb per mL light-sensitive solution

Calculated dose (12 to 20 mL for adults) is diluted in 50 mL of 5 percent dextrose in distilled water, infused intravenously over 10 to 15 minutes

Amphotericin B (Fungizone)

Reserved for antimony failures

Dosage: 0.5 to 1.0 mg per kg every other day for up to eight weeks; total dosage is 1.5 to 2 g for the treatment period

Pentamidine isethionate (Pentam 300)

Dosage: 2 mg per kg intramuscularly every other day for seven days

Toxic effects: damage to pancreas, kidney, or bone marrow may be irreversible

May induce diabetes mellitus

Others

Topical paromomycin is effective with L. major and L. mexicana. It can be combined with antimonials to reduce the number of injections.

Oral antifungals have demonstrated conflicting results, although some good results have been achieved with L. mexicana19 and L. major.18

Allopurinol (Zyloprim) incorporates into parasite RNA with lethal effect. Studies are conflicting, and it is not recommended, although there is synergistic activity with antimonials.1114

Heat1516 and cryotherapy17 show good results in uncontrolled trials.

Excision is not recommended because of the high risk of local relapse and disfiguration.


Information from references 11 through 19.

The Authors

WILLIAM H. MARKLE, M.D., is assistant professor of family medicine at the University of Pittsburgh School of Medicine and family practice residency program director at the University of Pittsburgh Medical Center (UPMC), McKeesport, Pa. He is a graduate of the Penn State Milton S. Hershey Medical Center, Hershey, Pa., and completed a residency at Virginia Commonwealth University, Blackstone Family Practice Center, Blackstone, Va. He received a diploma in tropical medicine and hygiene at Mahidol University, Bangkok, Thailand.

KHALDOUN MAKHOUL, M.D., is currently in private practice in Easton, Pa. He is a graduate of the University of Aleppo Faculty of Medicine, Aleppo, Syria, and completed a family practice residency at UPMC McKeesport.

Address correspondence to William H. Markle, M.D., University of Pittsburgh Medical Center, McKeesport Family Practice Residency, 3518 Fifth Ave., Pittsburgh, PA 15261 (e-mail: marklew@upmc.edu). Reprints are not available from the authors.

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.

Figure 1 provided by Eric J. Sheltra.

 

REFERENCES

1. Dedet JP, Pratlong F. Leishmaniasis. In: Manson P, Cook GC, Zumla A, eds. Manson’s Tropical diseases. 21st ed. London: Saunders, 2003:1339–64.

2. Herwaldt BL. Leishmaniasis. Lancet. 1999;354:1191–9.

3. Cope SE, Schultz GW, Richards AL, Savage HM, Smith GC, Mitchell CJ, et al. Assessment of arthropod vectors of infectious diseases in areas of U.S. troop deployment in the Persian Gulf. Am J Trop Med Hyg. 1996;54:49–53.

4. Hyams KC, Hanson K, Wignall FS, Escamilla J, Oldfield EC 3d. The impact of infectious diseases on the health of U.S. troops deployed to the Persian Gulf during operations Desert Shield and Desert Storm. Clin Infect Dis. 1995;20:1497–504.

5. McNeil DG Jr. A region inflamed: medicine; hundreds of U.S. troops infected by parasite borne by sand flies, Army says. New York Times December 6, 2003:A,8.

6. Centers for Disease Control and Prevention (CDC). . Cutaneous leishmaniasis in U.S. military personnel—Southwest/Central Asia, 2002–2003. MMWR Morb Mortal Wkly Rep. 2003;52:1009–12.

7. Lane RP. Phlebotomine sandflies. In: Manson P, Cook GC, Zumla A, eds. Manson’s Tropical diseases. 21st ed. London: Saunders, 2003:1733–41.

8. WHO fact sheet. The leishmaniases and leishmania/HIV coinfections. Accessed October 16, 2003, at: http://www.who.int/inf-fs/en/fact116.html.

9. Magill AJ. Leishmaniasis. In: Hunter GW, Strickland GT, eds. Hunter’s Tropical medicine and emerging infectious diseases. 8th ed. Philadelphia: Saunders, 2000:665–87.

10. Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA Jr, Magill AJ, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis. 1998;27:1457–64.

11. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med. 1992;326:741–4.

12. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med. 1997;126:232–6.

13. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2002;41:521–4.

14. Llanos-Cuentas A, Echevarria J, Cruz M, La Rosa A, Campos P, Campos M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis. 1997;25:677–84.

15. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. 1990;42:43–50.

16. Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, Garcia MF, Lazaro GJ, et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg. 1997;57:309–12.

17. Gurei MS, Tatli N, Ozbilge H, Erel O, Seyrek A, Kocyigit A, et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol. 2000;30:169–76.

18. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused byLeishmania major. N Engl J Med. 2002;346:891–5.

19. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. BMJ. 2003;326:377–82.

20. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998;351:1540–3.

21. Kroeger A, Avila EV, Morison L. Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: cluster randomised trial. BMJ. 2002;325:810–3.


Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article